Transcription factor 12‐mediated self‐feedback regulatory mechanism is required in DUX4 fusion leukaemia

Abstract

BackgroundIGH::DUX4 is frequently observed in 4% B‐cell acute lymphoblastic leukaemia patients. Regarding the IGH::DUX4‐driven transactivation and alternative splicing, which are the main reasons behind this acute leukaemia outbreak, it remains unclear how transcriptional cofactors contribute to this oncogenic process. Further investigation is required to elucidate their specific role in leukaemogenesis.MethodsIn order to investigate the cofactors of IGH::DUX4, integrated mining of Chromatin immunoprecipitation (ChIP)‐sequencing and RNA‐sequencing of leukaemia cells and patient samples were conducted. Furthermore, to elucidate the synergistic interaction between transcription factor 12 (TCF12) and IGH::DUX4, knockdown and knockout experiment, mammalian two‐hybridisation assay, co‐immunoprecipitation and in situ proximity ligation assays were carried out. Additionally, to further investigate the direct interaction between TCF12 and IGH::DUX4, AI‐based structural simulations were utilised. Finally, to validate the synergistic role of TCF12 in promoting IGH::DUX4 leukaemia, cell proliferation, apoptosis and drug sensitivity experiments were performed.ResultsIn this study, we observed that the IGH::DUX4 target gene TCF12 might be an important cofactor/helper for this oncogenic driver. The co‐expression of IGH::DUX4 and TCF12 resulted in enhanced DUX4‐driven transactivation. Supportively, knockdown and knockout of TCF12 significantly reduced expression of IGH::DUX4‐driven target genes in leukaemia REH (a precursor B‐cell leukaemia cell line) and NALM‐6 cells (a precursor B‐cell leukaemia cell line). Consistently, in TCF12 knockout cells, the expression of structure‐based TCF12 mutant, but not wild‐type TCF12, failed to restore the TCF12–IGH::DUX4 crosstalk and the synergistic transactivation. More importantly, the breakdown in TCF12–IGH::DUX4 cooperation impaired IGH::DUX4‐driven leukaemia cell survival, caused sensitivity to the chemotherapy.ConclusionsAltogether, these results helped to define a previously unrecognised TCF12‐mediated positive self‐feedback regulatory mechanism in IGH::DUX4 leukaemia, which holds the potential to function as a pivotal drug target for the management of this particular form of leukaemia.Highlights Transcription factor 12 (TCF12) is a new novel cofactor in IGH::DUX4 transcriptional complexes/machinery. TCF12 mediates a positive self‐feedback regulatory mechanism in IGH::DUX4‐driven oncogenic transaction. IGH::DUX4–TCF12 structure/cooperation might represent a potent target/direction in future drug design against B‐cell acute lymphoblastic leukaemia.